Hurthle cell cancer: Consider systemic therapy…Larotrectinib or entrectinib for patients with NTRK gene fusion-positive advanced solid tumors.
Sensitive: C1 - Off-label
(Approved for Solid Tumor)
entrectinib (Rozlytrek ®) is accepted for use within NHSScotland
entrectinib (Rozlytrek) is accepted for use within NHSScotland...as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion